on ABL DIAGNOSTICS (EPA:ABLD)
ABL Diagnostics Files Takeover Bid for IntegraGen
ABL Diagnostics, operating in molecular diagnostics solutions, has announced a takeover bid for IntegraGen. The acquisition effort targets IntegraGen's assets, a firm focused on genomic analysis in oncology and rare genetic diseases. Currently, IntegraGen is undergoing judicial reorganization at the Commercial Court of Évry.
This move aligns with ABL Diagnostics' growth strategy, seeking external growth opportunities complementary to their current offerings. The proposal remains contingent upon the court’s approval, with no assurance yet that ABL Diagnostics will secure the acquisition. ABL Diagnostics remains committed to informing the market of significant developments.
The press release details contain forward-looking statements subject to risks and court approval uncertainties, as per EU regulations.
R. H.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all ABL DIAGNOSTICS news